To evaluate the clinical impact of continuing versus holding GLP-1 and GIP agonists prior to upper endoscopy, specifically regarding clinically significant residual gastric volume (RGV) and the rationale for this evaluation.
Key Findings:
No clinically significant RGV was observed in either group during the trial, indicating that continuing GLP-1/GIP agonists may not pose a risk during procedures.
The study found that continuing GLP-1/GIP agonists did not lead to increased risk of clinically significant RGV compared to holding the medication, suggesting a need for practice guideline updates.
Interpretation:
Continuing GLP-1/GIP agonists prior to upper endoscopy is noninferior to holding the medication, suggesting that current guidelines regarding medication management before procedures may need reevaluation.
Limitations:
The study was limited to specific elective upper endoscopic procedures, which may not represent all clinical scenarios.
Results may not be generalizable to all patient populations or types of procedures, and potential biases or confounding factors were not fully addressed.
Conclusion:
Continuing GLP-1/GIP agonists before upper endoscopy does not increase the risk of clinically significant RGV, supporting a potential change in practice guidelines to improve patient care.
by Akram I. Ahmad, Samita Garg, Jeffrey Jacobs, Zaid Ansari, Tasneem Jamal Al-Din, Ashraf Almomani, Sara Valencia, John Vargo, Arjun Chatterjee, Hassan Siddiki, Liang Hong, Michael A. Nicolas, Alaina Miller, Tilak Shah
